233 related articles for article (PubMed ID: 2112067)
21. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
[TBL] [Abstract][Full Text] [Related]
22. Correlation of plasma insulin and insulin-like growth factor-I with indices of androgen transport and metabolism in women with polycystic ovary syndrome.
Sharp PS; Kiddy DS; Reed MJ; Anyaoku V; Johnston DG; Franks S
Clin Endocrinol (Oxf); 1991 Sep; 35(3):253-7. PubMed ID: 1742883
[TBL] [Abstract][Full Text] [Related]
23. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome.
Eldar-Geva T; Spitz IM; Groome NP; Margalioth EJ; Homburg R
Hum Reprod; 2001 Dec; 16(12):2552-6. PubMed ID: 11726573
[TBL] [Abstract][Full Text] [Related]
24. Which hormone tests for the diagnosis of polycystic ovary syndrome?
Robinson S; Rodin DA; Deacon A; Wheeler MJ; Clayton RN
Br J Obstet Gynaecol; 1992 Mar; 99(3):232-8. PubMed ID: 1296589
[TBL] [Abstract][Full Text] [Related]
25. Effects of Dietary Approach to Stop Hypertension diet on androgens, antioxidant status and body composition in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial.
Azadi-Yazdi M; Karimi-Zarchi M; Salehi-Abargouei A; Fallahzadeh H; Nadjarzadeh A
J Hum Nutr Diet; 2017 Jun; 30(3):275-283. PubMed ID: 28466507
[TBL] [Abstract][Full Text] [Related]
26. Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia.
Rajkhowa M; Bicknell J; Jones M; Clayton RN
Fertil Steril; 1994 Apr; 61(4):605-12. PubMed ID: 8150099
[TBL] [Abstract][Full Text] [Related]
27. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
28. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease.
Anttila L; Ding YQ; Ruutiainen K; Erkkola R; Irjala K; Huhtaniemi I
Fertil Steril; 1991 Jun; 55(6):1057-61. PubMed ID: 1903726
[TBL] [Abstract][Full Text] [Related]
29. Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome?
Cibula D; Hill M; Fanta M; Sindelka G; Zivny J
Hum Reprod; 2001 May; 16(5):940-4. PubMed ID: 11331641
[TBL] [Abstract][Full Text] [Related]
30. The role of nutrition and insulin in the regulation of sex hormone binding globulin.
Franks S; Kiddy DS; Hamilton-Fairley D; Bush A; Sharp PS; Reed MJ
J Steroid Biochem Mol Biol; 1991 Nov; 39(5B):835-8. PubMed ID: 1954173
[TBL] [Abstract][Full Text] [Related]
31. Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective.
Pasquali R; Zanotti L; Fanelli F; Mezzullo M; Fazzini A; Morselli Labate AM; Repaci A; Ribichini D; Gambineri A
J Clin Endocrinol Metab; 2016 May; 101(5):2013-22. PubMed ID: 26964728
[TBL] [Abstract][Full Text] [Related]
32. The association of body mass index and biochemical hyperandrogenaemia in women with and without polycystic ovary syndrome.
Yasmin E; Balen AH; Barth JH
Eur J Obstet Gynecol Reprod Biol; 2013 Feb; 166(2):173-7. PubMed ID: 23102586
[TBL] [Abstract][Full Text] [Related]
33. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis of the decreased androgen levels in obese men.
Giagulli VA; Kaufman JM; Vermeulen A
J Clin Endocrinol Metab; 1994 Oct; 79(4):997-1000. PubMed ID: 7962311
[TBL] [Abstract][Full Text] [Related]
36. Circulating anti-Müllerian hormone levels in relation to nutritional status and selected adipokines levels in polycystic ovary syndrome.
Olszanecka-Glinianowicz M; Madej P; Owczarek A; Chudek J; Skałba P
Clin Endocrinol (Oxf); 2015 Jul; 83(1):98-104. PubMed ID: 25440474
[TBL] [Abstract][Full Text] [Related]
37. [Plasma renin and aldosterone levels in obese and non-obese women with polycystic ovary syndrome].
Mejia-Montilla J; Reyna-Villasmil E; Torres-Cepeda D; Santos-Bolívar J; Reyna-Villasmil N; Bravo-Henríquez A
Endocrinol Nutr; 2012 Jan; 59(1):21-7. PubMed ID: 22115703
[TBL] [Abstract][Full Text] [Related]
38. The impact of obesity on hormonal parameters in hirsute and nonhirsute women.
Bernasconi D; Del Monte P; Meozzi M; Randazzo M; Marugo A; Badaracco B; Marugo M
Metabolism; 1996 Jan; 45(1):72-5. PubMed ID: 8544780
[TBL] [Abstract][Full Text] [Related]
39. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.
Morin-Papunen LC; Koivunen RM; Ruokonen A; Martikainen HK
Fertil Steril; 1998 Apr; 69(4):691-6. PubMed ID: 9548159
[TBL] [Abstract][Full Text] [Related]
40. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
Apter D; Bützow T; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
